Your browser doesn't support javascript.
loading
Cancer-free survival following alemtuzumab induction in heart transplantation.
Chivukula, S; Shullo, M A; Kormos, R L; Bermudez, C A; McNamara, D M; Teuteberg, J J.
Afiliación
  • Chivukula S; School of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Shullo MA; Department of Pharmacy and Therapeutics, Pittsburgh, Pennsylvania.
  • Kormos RL; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Bermudez CA; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • McNamara DM; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Teuteberg JJ; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: teuteberggjj@upmc.edu.
Transplant Proc ; 46(5): 1481-8, 2014 Jun.
Article en En | MEDLINE | ID: mdl-24935317
BACKGROUND: The malignancy rate after alemtuzumab (C-1H) induction in cardiac transplantation is unknown. METHODS: A retrospective analysis from a single center for all patients that underwent cardiac transplantation from January 2000 to January 2011 and that had no history of malignancy before transplantation was performed. Patients induced with alemtuzumab were compared with a group of patients receiving thymoglobulin or no induction and assessed for 4-year cancer-free post-heart transplantation survival. RESULTS: Of 402 patients included, 185 (46.0%) received alemtuzumab, 56 (13.9%) thymoglobulin, and 161 (40.0%) no induction. Baseline characteristics did not differ between groups: mean age 54.0 years, male 77.1%, white 88.6%, ischemic cardiomyopathy 49.0%. The calcineurin inhibitor was tacrolimus in 98.9% of alemtuzumab patients, 98.2% of thymoglobulin patients, and 87.0% of the noninduced (P < .001). The secondary agent was mycophenolate mofetil in all but 16 noninduced patients (9.9%), who received azathioprine. The 4-year cancer-free survival did not differ between groups: 88.1% alemtuzumab, 87.5% thymoglobulin, 88.2% noninduction; P = .088. The 4-year nonskin cancer-free survival was 96.8% for the alemtuzumab group, 96.4% for the thymoglobulin group, and 95.7% for the noninduced; P = .899. CONCLUSIONS: Neither the 4-year cancer-free survival nor the 4-year nonskin cancer-free survival differed between the alemtuzumab, thymoglobulin, and noninduced groups.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Corazón / Anticuerpos Monoclonales Humanizados / Neoplasias Tipo de estudio: Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Transplant Proc Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Corazón / Anticuerpos Monoclonales Humanizados / Neoplasias Tipo de estudio: Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Transplant Proc Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos